SSSS vs XFOR Comparison

SuRo Capital Corp is a non-diversified closed-end management investment company. The Company's investment objective is to maximize total return, mainly through capital gains on equity and equity-related investments, and to a lesser extent, income from debt investments. It invests mainly in equity securities of rapidly growing, venture capital-backed emerging companies. Investments are made through direct investments, secondary marketplaces, negotiations with selling stockholders, and investment funds or special purpose vehicles (SPVs). The Company may also invest in private credit, founder equity and warrants, and private investment in public equity (PIPE) transactions of special purpose acquisition companies (SPACs).

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.